These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12466154)

  • 1. Effect of a growth hormone receptor antagonist on proliferative diabetic retinopathy.
    Chantelau E
    Ophthalmology; 2002 Dec; 109(12):2187; author reply 2187-8. PubMed ID: 12466154
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy.
    Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group
    Ophthalmology; 2001 Dec; 108(12):2266-72. PubMed ID: 11733269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pegvisomant decreases growth hormone to nothing].
    Krankenpfl J; 2004; 42(1-2):16-7. PubMed ID: 15116768
    [No Abstract]   [Full Text] [Related]  

  • 4. [Drug therapy of acromegaly].
    Krankenpfl J; 2004; 42(7-10):260-1. PubMed ID: 15675419
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of acromegaly.
    Utiger RD
    N Engl J Med; 2000 Apr; 342(16):1210-1. PubMed ID: 10770989
    [No Abstract]   [Full Text] [Related]  

  • 6. [Growth hormone-receptor antagonist pegvisomant].
    Herrmann BL; Strasburger CJ
    Dtsch Med Wochenschr; 2004 Oct; 129(44):2356-8. PubMed ID: 15497105
    [No Abstract]   [Full Text] [Related]  

  • 7. GH receptor antagonist: mechanism of action and clinical utility.
    Surya SK; Barkan AL
    Rev Endocr Metab Disord; 2005 Jan; 6(1):5-13. PubMed ID: 15711909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Growth hormone receptor antagonists: potential indications].
    Muller AF; Janssen JA; de Herder WW; van der Lely AJ
    Ned Tijdschr Geneeskd; 2001 Jan; 145(2):69-73. PubMed ID: 11225259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone receptor antagonists.
    van der Lely AJ; Kopchick JJ
    Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
    van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
    J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer and the potential place for growth hormone receptor antagonist therapy.
    Friend KE
    Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S121-3. PubMed ID: 11527083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Place of pegvisomant in acromegaly.
    Ho KK
    Lancet; 2001 Nov; 358(9295):1743-4. PubMed ID: 11734225
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical review 166: Growth hormone receptor antagonists.
    Muller AF; Kopchick JJ; Flyvbjerg A; van der Lely AJ
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1503-11. PubMed ID: 15070905
    [No Abstract]   [Full Text] [Related]  

  • 14. Medical progress: Acromegaly.
    Melmed S
    N Engl J Med; 2006 Dec; 355(24):2558-73. PubMed ID: 17167139
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
    N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights from growth hormone receptor blockade.
    Muller AF; van der Lely AJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1072-9. PubMed ID: 15535428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACROSTUDY: an overview.
    Trainer PJ
    Horm Res; 2007; 68 Suppl 5():68-9. PubMed ID: 18174712
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment for growth hormone disorder.
    FDA Consum; 2003; 37(4):4. PubMed ID: 12971329
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of modulation of GH/IGF-I axis in the development of diabetic proliferative retinopathy.
    Genovese S; Riccardi G
    J Endocrinol Invest; 2003; 26(8 Suppl):114-6. PubMed ID: 15233225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.